Advanced search Help
Searching for terms: EXACT: "Siddalingaiah, Simi V." in: author
Clear all search criteria
Only 2/3! You are seeing results from the Public Collection, not the complete Full Collection. Sign in to search everything (see eligibility).
-
Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials [December 22, 2020]
From the Document: "Operation Warp Speed (OWS) is an interagency partnership between the Department of Health and Human Services (HHS) and the Department of Defense (DOD) that coordinates federal efforts to accelerate the development, acquisition, and distribution of COVID-19 [coronavirus disease 2019] medical countermeasures. Collaborating HHS components include the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA). Although the stated goals of OWS include therapeutics and diagnostics, most of the money awarded to date has focused on vaccines. This Insight summarizes OWS's vaccine-related contracts, including those for ancillary vaccination materials (e.g., needles and vials)."
Library of Congress. Congressional Research Service
Siddalingaiah, Simi V.
2020-12-22
-
Supply Chain Considerations for COVID-19 Vaccine Manufacturing [November 23, 2020]
From the Document: "The development of a vaccine for the Coronavirus Disease 2019 (COVID-19) pandemic has been of concern to Congress, as vaccination can be one of the most effective methods of preventing disease spread. On November 18, 2020, Pfizer/BioNTech announced that an interim analysis found its newly developed vaccine to be '95% effective against COVID-19' and has since filed for an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration. On November 16, 2020, Moderna announced that its vaccine, tentatively evaluated as 94.5% effective, will also be submitted for an EUA. According to media reports, 'Moderna said it would have 20 million doses ready by the end of 2020; Pfizer said it would have about 50 million by then.' Providing COVID-19 vaccines--complex, specially manufactured and distributed products--involves significant supply chain considerations. Needed supplies may be limited in quantity and face global competition. This Insight provides an overview of selected supplies required to manufacture vaccines and ancillary vaccination materials that may pose supply chain challenges and describes the federal government's role in this process. It does not cover particular contracts issued, or supplies potentially required for transportation, distribution, and administration of eventual vaccines."
Library of Congress. Congressional Research Service
Siddalingaiah, Simi V.
2020-11-23
1
